Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study for GSK573719 in Japanese

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient.~* A signed and dated written informed consent prior to study participation.~* Japanese subjects 40 years of age or older at Visit 1.~* Male or female subjects. A female is eligible if she is of: Non-child bearing potential or Child bearing potential agrees to one of the contraceptive methods.~* Subjects with a clinical history of COPD in accordance with the definition by COPD domestic guideline.~* Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Visit 1.~* Subject with a measured post-salbutamol forced expiratory volume/forced vital capacity (FEV1/FVC) ratio of \<70% and Subjects with a measured post-salbutamol FEV1 \<80% of predicted normal values.~Exclusion Criteria (Visit 1):~* Women who are pregnant or lactating or are planning on becoming pregnant during the study.~* A current diagnosis of asthma.~* Known respiratory disorders other than COPD.~* Subjects with historical or current evidence of clinically significant abnormalities that are uncontrolled.~* A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD.~* Allergy or hypersensitivity to muscarinic, beta2-agonist, lactose/milk protein or magnesium stearate or a condition that contraindicates participation.~* Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.~* Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).~* An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1.~* Significantly abnormal finding from clinical chemistry or hematology, tests at Visit 1.~* Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day.~* Regular use (prescribed every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol) via nebulized therapy.~* Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1.~* A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.~* Affiliation with Investigator Site.~* Previous use of GSK573719, the GSK573719/GW642444 combination.~* Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer).~Exclusion Criteria (Visit 2):~- COPD Exacerbation during run-in period: Subject must not have experienced a COPD exacerbation or a lower respiratory tract infection during run-in or at Visit 2.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719 (Type: EXPERIMENTAL): 125mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).